Skip to main content

Oregon State Flag An official website of the State of Oregon »

Drug affordability review

The Prescription Drug Affordability Board (PDAB) will begin affordability reviews during the first five board meetings in 2024. In January, the board will review insulin products. In February, March, April, and May, the board will review three prescription drugs per meeting. The board’s review list is posted below. Click on the drug name to read the affordability review drug report. Reports will be posted one week before the board meeting. Written comments specific to drugs under review and submitted by the deadlines will be included in the drug reports. To submit a comment for affordability review, complete and submit the public comment form.

Board calendar for affordability review of insulin, prescription drugs
Board meeting month and date Drugs
Estimated time per drug to review, discuss and vote Time per drug for public comment or testimony * Written public comment for drug affordability review: deadline for written materials, information specific to drugs under review
Jan. 26
Insulin:

Tresiba
Tresiba FlexTouch

Humulin R U-500 KwikPen

20 minutes each 20 minutes each Jan. 5, 2024 by 5 p.m.
Feb. 21 Group 1:
Ozempic
Trulicity
Shingrix


20 minutes each 20 minutes each Jan. 31, 2024 by 5 p.m.
Mar. 20 Group 2:
Ocrevus
Entyvio
Inflectra
20 minutes each 20 minutes each Feb. 28, 2024 by 5 p.m.
Apr. 17 Group 3:
Cosentyx
Skyrizi
Tremfya
20 minutes each 20 minutes each Mar. 31, 2024 by 5 p.m.
May 15 Group 4:
Vyvanse
Genvoya
Triumeq
20 minutes each 20 minutes each Apr. 30, 2024 by 5 p.m.
* Times may vary depending on the number of people and organizations providing public comment